These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8497347)

  • 21. [Combined estrogen-progestagen contraception and glucid and water-sodium metabolism].
    Belaisch J; Hommais-loufrani B
    Contracept Fertil Sex (Paris); 1988 Feb; 16(2):3-7. PubMed ID: 12342001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancing oral contraceptive success: the potential of new formulations.
    Kaunitz AM
    Am J Obstet Gynecol; 2004 Apr; 190(4 Suppl):S23-9. PubMed ID: 15105795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Oral contraception: advantages of estrogen reduction].
    Cohen J
    Contracept Fertil Sex (Paris); 1993 Jun; 21(6):489-94. PubMed ID: 12318239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
    Ferreira AC; Montes MB; Franceschini SA; Toloi MR
    Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The latest progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Oral contraception: evolution of concepts over the last thirty years].
    Belaisch J; Hommais-loufrani B
    Contracept Fertil Sex (Paris); 1987 Nov; 15(11 Suppl):1-8. PubMed ID: 12281408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Disadvantages of third generation progestins].
    Sitruk-ware R
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developments in new progestagens for oral contraception.
    Eyong E
    IPPF Med Bull; 1987 Apr; 21(2):3-4. PubMed ID: 12268598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OC practice guidelines: minimizing side effects.
    Darney PD
    Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral contraceptives and venous thromboembolism: an epidemiological review.
    Lidegaard O
    Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of body composition during low-dose estrogen oral contraceptives treatment.
    Franchini M; Caruso C; Nigrelli S; Poggiali C
    Acta Eur Fertil; 1995; 26(2):69-73. PubMed ID: 9098463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: are there advantages?
    Sobel NB
    Obstet Gynecol Clin North Am; 1994 Jun; 21(2):299-319. PubMed ID: 7936546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New progestins--clinical experiences: gestodene.
    Shoupe D
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1562-8. PubMed ID: 8178907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oral contraception: disadvantages of estrogen reduction].
    Denis C
    Contracept Fertil Sex (Paris); 1993 Jun; 21(6):481-8. PubMed ID: 12318238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Progestins and arterial disease].
    Rozenbaum H
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):344-52. PubMed ID: 12280205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.